vs
Amneal Pharmaceuticals, Inc.（AMRX）与COMPASS MINERALS INTERNATIONAL INC（CMP）财务数据对比。点击上方公司名可切换其他公司
Amneal Pharmaceuticals, Inc.的季度营收约是COMPASS MINERALS INTERNATIONAL INC的1.8倍（$722.5M vs $396.1M），Amneal Pharmaceuticals, Inc.净利率更高（10.8% vs 4.7%，领先6.1%），COMPASS MINERALS INTERNATIONAL INC同比增速更快（28.9% vs 3.9%），过去两年COMPASS MINERALS INTERNATIONAL INC的营收复合增速更高（4.3% vs 1.5%）
Amneal Pharmaceuticals是一家美国上市制药企业，核心业务涵盖仿制药及专科药物的研发、生产与分销，总部位于新泽西州布里奇沃特，是美国规模最大的仿制药生产商之一。
指南针矿产国际是一家美国上市矿产企业，总部位于堪萨斯州欧弗兰帕克，是盐、氯化镁和硫酸钾等产品的领先生产商。公司面向北美和英国客户供应经处理与未经处理的散装道路除冰盐，同时向全球种植者提供植物营养产品，此外也生产民用除冰、水质调节产品及相关商用产品。
AMRX vs CMP — 直观对比
营收规模更大
AMRX
是对方的1.8倍
$396.1M
营收增速更快
CMP
高出25.0%
3.9%
净利率更高
AMRX
高出6.1%
4.7%
两年增速更快
CMP
近两年复合增速
1.5%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $722.5M | $396.1M |
| 净利润 | $78.0M | $18.6M |
| 毛利率 | 44.3% | 16.0% |
| 营业利润率 | — | 9.2% |
| 净利率 | 10.8% | 4.7% |
| 营收同比 | 3.9% | 28.9% |
| 净利润同比 | 217.0% | 178.8% |
| 每股收益（稀释后） | $0.19 | $0.43 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMRXCMP
| Q1 26 | $722.5M | — | ||
| Q4 25 | $814.3M | $396.1M | ||
| Q3 25 | $784.5M | $227.5M | ||
| Q2 25 | $724.5M | $214.6M | ||
| Q1 25 | $695.4M | $494.6M | ||
| Q4 24 | $730.5M | $307.2M | ||
| Q3 24 | $702.5M | $208.8M | ||
| Q2 24 | $701.8M | $202.9M |
净利润AMRXCMP
| Q1 26 | $78.0M | — | ||
| Q4 25 | $35.1M | $18.6M | ||
| Q3 25 | $2.4M | $-7.2M | ||
| Q2 25 | $22.4M | $-17.0M | ||
| Q1 25 | $12.2M | $-32.0M | ||
| Q4 24 | $-31.1M | $-23.6M | ||
| Q3 24 | $-156.0K | $-48.3M | ||
| Q2 24 | $6.0M | $-43.6M |
毛利率AMRXCMP
| Q1 26 | 44.3% | — | ||
| Q4 25 | 36.5% | 16.0% | ||
| Q3 25 | 34.9% | 16.9% | ||
| Q2 25 | 39.5% | 19.2% | ||
| Q1 25 | 36.8% | 15.5% | ||
| Q4 24 | 36.0% | 11.2% | ||
| Q3 24 | 38.4% | 9.3% | ||
| Q2 24 | 35.6% | 16.1% |
营业利润率AMRXCMP
| Q1 26 | — | — | ||
| Q4 25 | 13.8% | 9.2% | ||
| Q3 25 | 9.0% | 5.3% | ||
| Q2 25 | 15.4% | 7.4% | ||
| Q1 25 | 14.4% | -0.6% | ||
| Q4 24 | 10.4% | 0.2% | ||
| Q3 24 | 12.6% | -14.3% | ||
| Q2 24 | 13.6% | 2.9% |
净利率AMRXCMP
| Q1 26 | 10.8% | — | ||
| Q4 25 | 4.3% | 4.7% | ||
| Q3 25 | 0.3% | -3.2% | ||
| Q2 25 | 3.1% | -7.9% | ||
| Q1 25 | 1.8% | -6.5% | ||
| Q4 24 | -4.3% | -7.7% | ||
| Q3 24 | -0.0% | -23.1% | ||
| Q2 24 | 0.9% | -21.5% |
每股收益（稀释后）AMRXCMP
| Q1 26 | $0.19 | — | ||
| Q4 25 | $0.10 | $0.43 | ||
| Q3 25 | $0.01 | — | ||
| Q2 25 | $0.07 | $-0.41 | ||
| Q1 25 | $0.04 | $-0.77 | ||
| Q4 24 | $-0.10 | $-0.57 | ||
| Q3 24 | $0.00 | $-1.17 | ||
| Q2 24 | $0.02 | $-1.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $46.7M |
| 总债务越低越好 | — | $890.0M |
| 股东权益账面价值 | — | $260.5M |
| 总资产 | — | $1.5B |
| 负债/权益比越低杠杆越低 | — | 3.42× |
8季度趋势，按日历期对齐
现金及短期投资AMRXCMP
| Q1 26 | — | — | ||
| Q4 25 | $282.0M | $46.7M | ||
| Q3 25 | $201.2M | $59.7M | ||
| Q2 25 | $71.5M | $79.4M | ||
| Q1 25 | $59.2M | $49.5M | ||
| Q4 24 | $110.6M | $45.8M | ||
| Q3 24 | $74.0M | $20.2M | ||
| Q2 24 | $43.8M | $12.8M |
总债务AMRXCMP
| Q1 26 | — | — | ||
| Q4 25 | $2.6B | $890.0M | ||
| Q3 25 | $2.6B | $839.8M | ||
| Q2 25 | $2.2B | $833.4M | ||
| Q1 25 | $2.2B | $807.6M | ||
| Q4 24 | $2.4B | $974.4M | ||
| Q3 24 | $2.4B | $921.2M | ||
| Q2 24 | $2.4B | $875.1M |
股东权益AMRXCMP
| Q1 26 | — | — | ||
| Q4 25 | $-70.8M | $260.5M | ||
| Q3 25 | $-109.5M | $234.1M | ||
| Q2 25 | $-112.1M | $249.8M | ||
| Q1 25 | $-131.7M | $236.5M | ||
| Q4 24 | $-109.3M | $263.0M | ||
| Q3 24 | $-93.4M | $316.6M | ||
| Q2 24 | $-57.5M | $352.1M |
总资产AMRXCMP
| Q1 26 | — | — | ||
| Q4 25 | $3.7B | $1.5B | ||
| Q3 25 | $3.6B | $1.5B | ||
| Q2 25 | $3.4B | $1.5B | ||
| Q1 25 | $3.4B | $1.5B | ||
| Q4 24 | $3.5B | $1.7B | ||
| Q3 24 | $3.5B | $1.6B | ||
| Q2 24 | $3.5B | $1.6B |
负债/权益比AMRXCMP
| Q1 26 | — | — | ||
| Q4 25 | — | 3.42× | ||
| Q3 25 | — | 3.59× | ||
| Q2 25 | — | 3.34× | ||
| Q1 25 | — | 3.41× | ||
| Q4 24 | — | 3.70× | ||
| Q3 24 | — | 2.91× | ||
| Q2 24 | — | 2.49× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-37.0M |
| 自由现金流经营现金流 - 资本支出 | — | $-59.8M |
| 自由现金流率自由现金流/营收 | — | -15.1% |
| 资本支出强度资本支出/营收 | — | 5.8% |
| 现金转化率经营现金流/净利润 | — | -1.99× |
| 过去12个月自由现金流最近4个季度 | — | $94.1M |
8季度趋势，按日历期对齐
经营现金流AMRXCMP
| Q1 26 | — | — | ||
| Q4 25 | $130.3M | $-37.0M | ||
| Q3 25 | $118.5M | $-6.9M | ||
| Q2 25 | $83.8M | $21.8M | ||
| Q1 25 | $7.4M | $186.9M | ||
| Q4 24 | $118.1M | $-4.1M | ||
| Q3 24 | $141.8M | $-12.7M | ||
| Q2 24 | $39.7M | $-6.8M |
自由现金流AMRXCMP
| Q1 26 | — | — | ||
| Q4 25 | $108.5M | $-59.8M | ||
| Q3 25 | $106.2M | $-22.8M | ||
| Q2 25 | $61.0M | $3.8M | ||
| Q1 25 | $-5.8M | $172.9M | ||
| Q4 24 | $102.9M | $-25.9M | ||
| Q3 24 | $124.8M | $-33.6M | ||
| Q2 24 | $29.0M | $-21.5M |
自由现金流率AMRXCMP
| Q1 26 | — | — | ||
| Q4 25 | 13.3% | -15.1% | ||
| Q3 25 | 13.5% | -10.0% | ||
| Q2 25 | 8.4% | 1.8% | ||
| Q1 25 | -0.8% | 35.0% | ||
| Q4 24 | 14.1% | -8.4% | ||
| Q3 24 | 17.8% | -16.1% | ||
| Q2 24 | 4.1% | -10.6% |
资本支出强度AMRXCMP
| Q1 26 | — | — | ||
| Q4 25 | 2.7% | 5.8% | ||
| Q3 25 | 1.6% | 7.0% | ||
| Q2 25 | 3.2% | 8.4% | ||
| Q1 25 | 1.9% | 2.8% | ||
| Q4 24 | 2.1% | 7.1% | ||
| Q3 24 | 2.4% | 10.0% | ||
| Q2 24 | 1.5% | 7.2% |
现金转化率AMRXCMP
| Q1 26 | — | — | ||
| Q4 25 | 3.72× | -1.99× | ||
| Q3 25 | 50.00× | — | ||
| Q2 25 | 3.74× | — | ||
| Q1 25 | 0.61× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 6.62× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMRX
| Affordable Medicines net | $423.0M | 59% |
| AvKARE net | $166.0M | 23% |
| Specialty net | $133.0M | 18% |
CMP
| Highway Deicing Salt | $210.8M | 53% |
| Consumer Industrial Salt | $120.7M | 30% |
| Plant Nutrition | $60.8M | 15% |
| Transferred Over Time | $2.8M | 1% |
| Other | $1.0M | 0% |
